HRMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harmony Biosciences Holdings Inc (HRMY) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 to invest. The stock faces significant risks related to its main drug Wakix, with potential generic competition as early as 2026. While hedge funds are showing interest, the financial performance and analyst sentiment suggest caution. Without strong positive catalysts or proprietary trading signals, holding off on this investment is prudent.
The technical indicators are mixed. The MACD is positive and expanding, suggesting some bullish momentum, but the RSI is neutral at 38.456, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot point of 27.788, with key support at 26.959 and resistance at 28.617. Overall, the technical setup does not strongly favor a buy.
Hedge funds are significantly increasing their positions in the stock, with a 18208.08% increase in buying activity over the last quarter. Additionally, the stock has a 60% chance of gaining 14.12% in the next month based on historical candlestick patterns.
Analysts have downgraded the stock and lowered price targets due to risks surrounding Wakix's patent protection and potential generic competition. The financial performance in Q4 2025 showed a significant drop in net income (-54.55% YoY) and EPS (-54.12% YoY), raising concerns about profitability.
In Q4 2025, revenue increased by 21.12% YoY to $243.78M, indicating growth in sales. However, net income dropped sharply by 54.55% YoY to $22.49M, and EPS fell by 54.12% YoY to $0.39. Gross margin also declined slightly to 71.88%, down 1.49% YoY. The financials highlight revenue growth but significant profitability challenges.
Analysts are cautious, with several downgrades and lowered price targets. UBS lowered the price target to $36 (Neutral), Deutsche Bank to $30 (Hold), and BofA to $28 (Underperform). Analysts cite risks related to Wakix's patent protection and potential generic competition as key concerns. Mizuho is the only firm with an Outperform rating and a price target of $50, but this is an outlier.
